Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-741; Location: LEVEL 3, HALL B3; "Blinatumomab was applied for consolidation in 9 of 18 patients (50%). Nine of 18 (50%) patients have entered the maintenance therapy phase, of whom 6 received olverembatinib only, 2 received a combination of olverembatinib and chemotherapy, and 1 received a combination of dasatinib and chemotherapy due to financial issues... Olverembatinib-based regimen with lower-intensity chemotherapy showed promising outcomes with acceptable side effects as frontline therapy in patients with Ph+ ALL, warranting further trials to investigate better strategies. ALL: acute lymphoblastic leukemia, allo-HSCT: allogeneic hematopoietic stem cell transplantation, BCR::ABL1: breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1 fusion, CAR-T: chimeric antigen receptor T-cell, CMR: complete molecular remission, CR: complete response, IKZF1: Ikaros family zinc finger protein 1, PCR: polymerase chain reaction, Ph+: Philadelphia chromosome–positive, TKI: tyrosine..."
Retrospective data • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • IKZF1
|
|
Kezhi Huang MD PhD 1,2,3; Yiqing Li MD 1; Xuejie Jiang MD PhD 4; Cong Luo MD 5; Zeyu Luo MD 6; Wenjuan Yang MD 1; Hongyun Liu MD 1; Guoyang Zhang MD 1; Runhui Zheng MD 7; Guinian Huang MD 8; Wenzheng Pang MD 9; Xueyang Xing MD 10; Zhenqian Huang MD 11; Jixian Huang MD 12; Huashan Luo MD 13; Danian Nie MD 1
|